US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OPUS GENETICS INC

1.04

+0.04004.00%

Post-market: 1.01-0.0297-2.86%19:49 EDT

Volume:710.29K

Turnover:747.48K

Market Cap:62.05M

PE:-0.52

High:1.10

Open:0.9659

Low:0.9600

Close:1.00

Loading ...

Overview Company News Filings

Opus Genetics Shares Rise After Positive Trial Results for Eye Treatment

Opus Genetics Inc reports results for the quarter ended March 31 - Earnings Summary

Opus Genetics Inc. Reports Positive Q1 2025 Results with Encouraging OPGx-LCA5 Trial Data and $21.5M Fundraising

Opus Genetics Q1 EPS $(0.24) Beats $(0.25) Estimate, Sales $4.37M Beat $3.10M Estimate

Press Release: Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

Opus Genetics Inc expected to post a loss of 25 cents a share - Earnings Preview

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Opgx-Lca5 Gene Therapy Candidate

THOMSON REUTERS

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath

BRIEF-Mina Sooch Issues Open Letter To Opus Genetics' Stockholders

Mina Sooch: to Exercise Rights as a Stockholder by Voting 'Withhold' on Opus Genetics Board’s Nominees in Proposal 1 at AGM

THOMSON REUTERS

BRIEF-Opus Genetics says Mina Sooch Determined To Withdraw Her Slate Of Nominees For Election To Board

Mina Sooch - Determined to Withdraw Her Slate of Nominees for Election to Opus Genetics' Board at the Annual Meeting

THOMSON REUTERS

Opus Genetics Announces One-Month Clinical Data From Pediatric Patient in Phase 1/2 Trial of Opgx-Lca5 Gene Therapy in Inherited Retinal Diseases

THOMSON REUTERS

Opus Genetics- Second Pediatric Patient Recently Dosed, Pediatric Cohort Is Expected to Complete Enrollment in Q2 2025

THOMSON REUTERS

Opus Genetics- First Pediatric Patient Shows Encouraging Early Safety Profile, Meaningful Improvement in Visual Function at One Month

THOMSON REUTERS

Opus Genetics Inc -Initial Data From All Three Patients Anticipated in Q3 2025

THOMSON REUTERS

Opus Genetics Inc -Anticipates Pivotal Trial Could Initiate in Q1 2026

THOMSON REUTERS

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Party Time: Brokers Just Made Major Increases To Their Opus Genetics, Inc. (NASDAQ:IRD) Earnings Forecasts

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IRD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","market":"US","secType":"STK","nameCN":"OPUS GENETICS INC","latestPrice":1.04,"timestamp":1749240000000,"preClose":1,"halted":0,"volume":710289,"hourTrading":{"tag":"盘后","latestPrice":1.0103,"preClose":1.04,"latestTime":"19:49 EDT","volume":6997,"amount":7243.2063,"timestamp":1749253796288},"delay":0,"floatShares":52711500,"shares":59661197,"eps":-2.017439,"marketStatus":"Market Closed","change":0.04,"latestTime":"06-06 16:00:00 EDT","open":0.9659,"high":1.0954,"low":0.96,"amount":747484.0648029,"amplitude":0.1354,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.017439,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"listingDate":1100235600000,"exchange":"NASDAQ","adjPreClose":1,"preHourTrading":{"tag":"盘前","latestPrice":0.9949,"preClose":1,"latestTime":"09:26 EDT","volume":6955,"amount":6658.589028,"timestamp":1749216413439},"postHourTrading":{"tag":"盘后","latestPrice":1.0103,"preClose":1.04,"latestTime":"19:49 EDT","volume":6997,"amount":7243.2063,"timestamp":1749253796288},"volumeRatio":0.08149936732239109,"impliedVol":2.1502,"impliedVolPercentile":0.6299},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","floatShares":52711500,"roa":"-45.36%","roe":"-167.55%","lyrEps":-2.153504,"volumeRatio":0.08149936732239109,"shares":59661197,"dividePrice":0,"high":1.0954,"amplitude":0.1354,"preClose":1,"low":0.96,"week52Low":0.65,"pbRate":"12.23","psRate":"4.55","week52High":2.18,"institutionHeld":0,"latestPrice":1.04,"eps":-2.017439,"divideRate":0,"volume":710289,"delay":0,"ttmEps":-2.017439,"open":0.9659,"prevYearClose":1.19,"prevWeekClose":0.9945,"prevMonthClose":0.9945,"prevQuarterClose":0.9818,"fiveDayClose":0.9945,"twentyDayClose":0.9958,"sixtyDayClose":0.9307},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IRD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540979139","title":"Opus Genetics Shares Rise After Positive Trial Results for Eye Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2540979139","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540979139?lang=en_us&edition=fundamental","pubTime":"2025-06-02 22:51","pubTimestamp":1748875860,"startTime":"0","endTime":"0","summary":"Opus Genetics shares were up 22% at $1.21, after the company said it saw positive topline results from a pivotal Phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of chronic night driving impairment in keratorefractive patients with reduced mesopic vision.The biopharmaceutical company said the treatment is meant to help patients who undergo keratorefractive eye procedures, such as laser-assisted in situ keratomileusis.The study met its primary endpoint of a gain of three lines--or 15 letters--or more of distance vision improvement on a low-contrast chart in low light conditions after 15 days of dosing.Opus said the study showed a safety profile consistent with previous studies, with no new safety signals identified. No evidence of tachyphylaxis was observed in this study over the six-week period.The stock hit its 52-week low of 65 cents on April 10, and is down 27% in the past 12 months.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Opus Genetics Shares Rise After Positive Trial Results for Eye Treatment","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","BK4139"],"gpt_icon":0},{"id":"2535802354","title":"Opus Genetics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2535802354","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535802354?lang=en_us&edition=fundamental","pubTime":"2025-05-16 16:12","pubTimestamp":1747383170,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc reports results for the quarter ended March 31 - Earnings SummaryOpus Genetics Inc IRD.OQ reported a quarterly adjusted loss of 24 cents per share for the quarter ended March 31, hig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nL8N3RO0FL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD"],"gpt_icon":0},{"id":"2535477828","title":"Opus Genetics Inc. Reports Positive Q1 2025 Results with Encouraging OPGx-LCA5 Trial Data and $21.5M Fundraising","url":"https://stock-news.laohu8.com/highlight/detail?id=2535477828","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535477828?lang=en_us&edition=fundamental","pubTime":"2025-05-15 20:28","pubTimestamp":1747312122,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 15, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL7Pbrky:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","BK4139"],"gpt_icon":0},{"id":"2535730842","title":"Opus Genetics Q1 EPS $(0.24) Beats $(0.25) Estimate, Sales $4.37M Beat $3.10M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535730842","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535730842?lang=en_us&edition=fundamental","pubTime":"2025-05-15 20:18","pubTimestamp":1747311532,"startTime":"0","endTime":"0","summary":"Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.25) by 4 percent. This is a 17.24 percent increase over losses of $(0.29) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45434824/opus-genetics-q1-eps-0-24-beats-0-25-estimate-sales-4-37m-beat-3-10m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD"],"gpt_icon":0},{"id":"2535584444","title":"Press Release: Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535584444","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535584444?lang=en_us&edition=fundamental","pubTime":"2025-05-15 20:00","pubTimestamp":1747310400,"startTime":"0","endTime":"0","summary":"ARVO presentation highlights 12-month results from Phase 1/2 study that support potential of OPGx-LCA5 gene therapy to restore meaningful vision. Pediatric cohort of LCA5 study ongoing with initial multi-patient data anticipated in Q3 2025. OPGx-BEST1 on track for IND filing and initiation of Phase 1/2 trial with early data expected in Q1 2026. Leading healthcare investors provide funding to deliver on key milestones. RESEARCH TRIANGLE PARK, N.C., May 15, 2025  -- Opus Genetics, Inc. , a clinical-stage ophthalmic biopharmaceutical company developing important new therapies for the treatment of inherited retinal diseases  and other ophthalmic disorders , today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update.\"In the phentolamine eye drop pipeline, we look forward to near-term clinical data readouts from the Phase 3 data trials in dim light vision disturbances and in presbyopia. We ended the first quarter with a strong cash position,","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TM","BK4604","IRD","BK4588","BK4555","BK4099","BK4585","BK4139","03160"],"gpt_icon":0},{"id":"2533633834","title":"Opus Genetics Inc  expected to post a loss of 25 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2533633834","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533633834?lang=en_us&edition=fundamental","pubTime":"2025-05-06 20:33","pubTimestamp":1746534786,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc  expected to post a loss of25cents a share - Earnings Preview Opus Genetics Inc IRD.OQ IRD.O is expected to show a rise in quarterly revenue when it reports  results on May 8 (estima","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nL8N3RE1BE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD"],"gpt_icon":0},{"id":"2533687154","title":"Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Opgx-Lca5 Gene Therapy Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2533687154","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533687154?lang=en_us&edition=fundamental","pubTime":"2025-05-06 20:00","pubTimestamp":1746532809,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RE13S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","IRD"],"gpt_icon":0},{"id":"2533586036","title":"Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision","url":"https://stock-news.laohu8.com/highlight/detail?id=2533586036","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533586036?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446400,"startTime":"0","endTime":"0","summary":"Improvements in subjective and objective measures of efficacy observed at six months persisted for one year in patients with severe vision impairment from inherited retinal degeneration due to mutations in theLCA5gene. Administration of OPGx-LCA5 by subretinal injection was well toleratedby study participants. RESEARCH TRIANGLE PARK, N.C., May 05, 2025  -- Opus Genetics, Inc. , a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases  and other treatments for ophthalmic disorders , today announced one-year results from adult patients treated in the ongoing Phase 1/2 Study of its lead gene therapy candidate OPGx-LCA5. These results were presented yesterday at the 2025 annual meeting of the Association for Research in Vision and Ophthalmology , taking place May 4 – 7, 2025 in Salt Lake City, Utah. The presentation, entitled “Recovery of Cone-Mediated Vision in a Severe Ciliopathy after Gene Augmentation: One Year Results ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opus-genetics-announces-presentation-opgx-120000746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SR","BK4197","BK4007","KOL","OPGX","BK4139","BK4109","IRD","LCA"],"gpt_icon":0},{"id":"2527457964","title":"PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath","url":"https://stock-news.laohu8.com/highlight/detail?id=2527457964","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527457964?lang=en_us&edition=fundamental","pubTime":"2025-04-15 22:36","pubTimestamp":1744727760,"startTime":"0","endTime":"0","summary":"Feature Details Company Milestones and 2025 Catalysts Across Gene Therapy and Ophthalmic Programs. NEW YORK, April 15, 2025  -- PRISM MarketView today published a Q&A feature with Dr. George Magrath, Chief Executive Officer of Opus Genetics, Inc.  , a clinical-stage gene therapy company developing treatments for inherited retinal diseases  and broader ophthalmic conditions.Dr. George Magrath, Chief Executive Officer of Opus Genetics, Inc.In the interview, Dr. Magrath outlines Opus Genetics’ recent milestones, including:. Completion of enrollment in two Phase 3 clinical trials: VEGA-3 for presbyopia and LYNX-2 for post-LASIK night vision disturbances;FDA Fast Track designation for phentolamine ophthalmic solution to treat chronic night driving impairment; and. Upcoming data presentations for OPGx-LCA5, an AAV-based gene therapy targeting Leber congenital amaurosis 5.The feature also explores Opus Genetics’ strategy to seek to build a repeatable gene therapy platform and anticipated clin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/prism-marketview-spotlights-opus-genetics-143600589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4141","BK4007","LCA","IRD","MMAT"],"gpt_icon":0},{"id":"2526643881","title":"BRIEF-Mina Sooch Issues Open Letter To Opus Genetics' Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2526643881","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526643881?lang=en_us&edition=fundamental","pubTime":"2025-04-12 03:53","pubTimestamp":1744401184,"startTime":"0","endTime":"0","summary":"BRIEF-Mina Sooch Issues Open Letter To Opus Genetics' StockholdersApril 11 (Reuters) - Mina Sooch:MINA SOOCH: ISSUED OPEN LETTER TO OPUS GENETICS' STOCKHOLDERSMINA SOOCH: TO EXERCISE RIGHTS AS A STOCK","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QP1FB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2526648094","title":"Mina Sooch: to Exercise Rights as a Stockholder by Voting 'Withhold' on Opus Genetics Board’s Nominees in Proposal 1 at AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2526648094","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526648094?lang=en_us&edition=fundamental","pubTime":"2025-04-12 03:48","pubTimestamp":1744400913,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QP1FB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2526344358","title":"BRIEF-Opus Genetics says Mina Sooch Determined To Withdraw Her Slate Of Nominees For Election To Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2526344358","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526344358?lang=en_us&edition=fundamental","pubTime":"2025-04-10 05:45","pubTimestamp":1744235118,"startTime":"0","endTime":"0","summary":"BRIEF-Opus Genetics says Mina Sooch Determined To Withdraw Her Slate Of Nominees For Election To BoardApril 9  - Opus Genetics Inc IRD.O:MINA SOOCH - DETERMINED TO WITHDRAW HER SLATE OF NOMINEES FOR ELECTION TO OPUS GENETICS' BOARD AT THE ANNUAL MEETINGSource text: [ID:n0000921895-25-001042]Further company coverage: IRD.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN1YJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD"],"gpt_icon":0},{"id":"2526349362","title":"Mina Sooch - Determined to Withdraw Her Slate of Nominees for Election to Opus Genetics' Board at the Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2526349362","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526349362?lang=en_us&edition=fundamental","pubTime":"2025-04-10 05:08","pubTimestamp":1744232935,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN1YJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD"],"gpt_icon":0},{"id":"2525989673","title":"Opus Genetics Announces One-Month Clinical Data From Pediatric Patient in Phase 1/2 Trial of Opgx-Lca5 Gene Therapy in Inherited Retinal Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2525989673","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525989673?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:02","pubTimestamp":1744113753,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1HD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2525896753","title":"Opus Genetics- Second Pediatric Patient Recently Dosed, Pediatric Cohort Is Expected to Complete Enrollment in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2525896753","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525896753?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:02","pubTimestamp":1744113753,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1HD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2525896056","title":"Opus Genetics- First Pediatric Patient Shows Encouraging Early Safety Profile, Meaningful Improvement in Visual Function at One Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2525896056","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525896056?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:02","pubTimestamp":1744113753,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1HD:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD"],"gpt_icon":0},{"id":"2525589605","title":"Opus Genetics Inc -Initial Data From All Three Patients Anticipated in Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2525589605","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525589605?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:02","pubTimestamp":1744113753,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1HD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD"],"gpt_icon":0},{"id":"2525052896","title":"Opus Genetics Inc -Anticipates Pivotal Trial Could Initiate in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2525052896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525052896?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:02","pubTimestamp":1744113753,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1HD:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD"],"gpt_icon":0},{"id":"2525993228","title":"Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2525993228","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525993228?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:00","pubTimestamp":1744113600,"startTime":"0","endTime":"0","summary":"First pediatric patient shows encouraging early safety profile and meaningful improvement in visual function at one month A second pediatric patient was recently dosed, and the pediatric cohort is exp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057520/0/en/Opus-Genetics-Announces-One-Month-Clinical-Data-from-Pediatric-Patient-in-Phase-1-2-Trial-of-OPGx-LCA5-Gene-Therapy-in-Inherited-Retinal-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","LU0149725797.USD","LU0882574139.USD","IE00BZ1G4Q59.USD","BK4588","IE00BHPRN162.USD","BK4528","BK4007","BK4613","LU1363072403.SGD","KOL","LU0267386448.USD","BK4585","LU0971096721.USD","SAP","IE00BKVL7J92.USD","LCA","BK4006","BK4023","IE00B1BXHZ80.USD","CMC","LU0170899867.USD"],"gpt_icon":0},{"id":"2525790765","title":"Party Time: Brokers Just Made Major Increases To Their Opus Genetics, Inc. (NASDAQ:IRD) Earnings Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2525790765","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525790765?lang=en_us&edition=fundamental","pubTime":"2025-04-05 20:42","pubTimestamp":1743856969,"startTime":"0","endTime":"0","summary":"Celebrations may be in order for Opus Genetics, Inc.  shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts greatly increased their revenue estimates, suggesting a stark improvement in business fundamentals.Trump has pledged to \"unleash\" American oil and gas and these 15 US stocks have developments that are poised to benefit.Following the upgrade, the current consensus from Opus Genetics' three analysts is for revenues of US$17m in 2025 which - if met - would reflect a substantial 57% increase on its sales over the past 12 months. The loss per share is anticipated to greatly reduce in the near future, narrowing 37% to US$0.80. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$13m and losses of US$0.99 per share in 2025. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also redu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/party-time-brokers-just-made-124249859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ",".IXIC","IRD"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":72,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"IRD","fiscalQuarterEnding":"2025/03","expectedEps":-0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.32},{"market":"US","date":"2025-03-31","symbol":"IRD","fiscalQuarterEnding":"2024/12","expectedEps":-0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":-1.27},{"market":"US","date":"2024-11-12","symbol":"IRD","fiscalQuarterEnding":"2024/09","expectedEps":-0.3,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.29},{"market":"US","date":"2024-08-13","symbol":"IRD","fiscalQuarterEnding":"2024/06","expectedEps":-0.29,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"pre","actualEps":-0.3},{"market":"US","date":"2024-05-10","symbol":"IRD","fiscalQuarterEnding":"2024/03","expectedEps":-0.18,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715313600000,"reportTimeType":"pre","actualEps":-0.29}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1744430400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IRD","date":"2025-06-05","current":-1.007584,"percent":0.691275,"low":-2.964142,"twenty":-1.393136,"median":-1.233817,"eighty":-0.767038,"high":-0.560128,"avg":-1.227831,"sd":0.502598,"marketCap":59064585},"quantilePoints":[{"date":"2024-10-31","current":-2.785848,"twenty":-2.857166,"median":-2.64666,"eighty":-2.37374,"marketCap":39294383},{"date":"2024-11-08","current":-2.429259,"twenty":-2.692243,"median":-2.607554,"eighty":-2.476187,"marketCap":34264702},{"date":"2024-11-15","current":-1.225421,"twenty":-2.616468,"median":-2.568551,"eighty":-2.326813,"marketCap":33321637},{"date":"2024-11-22","current":-1.142487,"twenty":-2.607554,"median":-2.49612,"eighty":-1.192247,"marketCap":31066518},{"date":"2024-11-29","current":-1.288651,"twenty":-2.607554,"median":-2.173143,"eighty":-1.193702,"marketCap":35040987},{"date":"2024-12-06","current":-1.323479,"twenty":-2.603096,"median":-1.364112,"eighty":-1.225421,"marketCap":35988040},{"date":"2024-12-13","current":-1.288651,"twenty":-2.574123,"median":-1.335088,"eighty":-1.234669,"marketCap":35040987},{"date":"2024-12-20","current":-1.14597,"twenty":-2.527405,"median":-1.303163,"eighty":-1.16559,"marketCap":31161223},{"date":"2024-12-27","current":-1.253822,"twenty":-2.505202,"median":-1.288651,"eighty":-1.163268,"marketCap":34093933},{"date":"2025-01-03","current":-1.462793,"twenty":-2.49612,"median":-1.294455,"eighty":-1.172556,"marketCap":39776255},{"date":"2025-01-10","current":-1.683372,"twenty":-2.442631,"median":-1.320577,"eighty":-1.181843,"marketCap":45774262},{"date":"2025-01-17","current":-1.346698,"twenty":-2.224366,"median":-1.346698,"eighty":-1.20274,"marketCap":36619410},{"date":"2025-01-24","current":-1.335088,"twenty":-1.87928,"median":-1.335088,"eighty":-1.207384,"marketCap":36303725},{"date":"2025-01-31","current":-1.288651,"twenty":-1.676407,"median":-1.329284,"eighty":-1.218206,"marketCap":35040987},{"date":"2025-02-07","current":-1.416355,"twenty":-1.657832,"median":-1.323479,"eighty":-1.225421,"marketCap":38513517},{"date":"2025-02-14","current":-1.335088,"twenty":-1.648544,"median":-1.323479,"eighty":-1.239294,"marketCap":36303725},{"date":"2025-02-21","current":-1.288651,"twenty":-1.616038,"median":-1.323479,"eighty":-1.250654,"marketCap":35040987},{"date":"2025-02-28","current":-1.207384,"twenty":-1.525484,"median":-1.317674,"eighty":-1.232138,"marketCap":32831195},{"date":"2025-03-07","current":-1.160946,"twenty":-1.444218,"median":-1.31187,"eighty":-1.207384,"marketCap":31568457},{"date":"2025-03-14","current":-1.07968,"twenty":-1.411711,"median":-1.30026,"eighty":-1.1772,"marketCap":29358665},{"date":"2025-03-21","current":-1.335088,"twenty":-1.404745,"median":-1.30026,"eighty":-1.16559,"marketCap":36303725},{"date":"2025-03-28","current":-1.637559,"twenty":-1.525484,"median":-1.31187,"eighty":-1.1772,"marketCap":44528506},{"date":"2025-04-04","current":-0.76585,"twenty":-1.525484,"median":-1.306065,"eighty":-1.160946,"marketCap":44060874},{"date":"2025-04-11","current":-0.564318,"twenty":-1.462793,"median":-1.288651,"eighty":-1.14388,"marketCap":32466352},{"date":"2025-04-17","current":-0.581158,"twenty":-1.453505,"median":-1.288651,"eighty":-1.129154,"marketCap":33435158},{"date":"2025-04-25","current":-0.632466,"twenty":-1.414033,"median":-1.288651,"eighty":-1.081468,"marketCap":36387058},{"date":"2025-05-02","current":-0.741567,"twenty":-1.404745,"median":-1.288651,"eighty":-1.054291,"marketCap":42663825},{"date":"2025-05-09","current":-0.787263,"twenty":-1.404745,"median":-1.277041,"eighty":-0.791089,"marketCap":45292790},{"date":"2025-05-16","current":-0.737114,"twenty":-1.402423,"median":-1.253822,"eighty":-0.755291,"marketCap":43209631},{"date":"2025-05-23","current":-0.783669,"twenty":-1.393136,"median":-1.253822,"eighty":-0.759832,"marketCap":45938661},{"date":"2025-05-30","current":-0.771642,"twenty":-1.393136,"median":-1.251182,"eighty":-0.76585,"marketCap":45233661},{"date":"2025-06-05","current":-1.007584,"twenty":-1.393136,"median":-1.233817,"eighty":-0.767038,"marketCap":59064585}],"updateTime":1749257417971}}}